First Trust Advisors LP lessened its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 94.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,517 shares of the medical device company’s stock after selling 160,737 shares during the period. First Trust Advisors LP’s holdings in DexCom were worth $466,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of the business. FMR LLC grew its position in DexCom by 9.9% during the second quarter. FMR LLC now owns 10,824,306 shares of the medical device company’s stock valued at $791,799,000 after acquiring an additional 978,898 shares during the period. Janus Henderson Group PLC boosted its position in shares of DexCom by 101,699.8% in the second quarter. Janus Henderson Group PLC now owns 6,828,731 shares of the medical device company’s stock worth $499,522,000 after buying an additional 6,822,023 shares during the period. Vanguard Group Inc. boosted its position in shares of DexCom by 3.4% in the second quarter. Vanguard Group Inc. now owns 6,821,102 shares of the medical device company’s stock worth $498,963,000 after buying an additional 224,808 shares during the period. BlackRock Inc. boosted its position in shares of DexCom by 5.5% in the second quarter. BlackRock Inc. now owns 4,391,404 shares of the medical device company’s stock worth $321,232,000 after buying an additional 230,542 shares during the period. Finally, Ameriprise Financial Inc. boosted its position in shares of DexCom by 18.2% in the second quarter. Ameriprise Financial Inc. now owns 3,948,468 shares of the medical device company’s stock worth $288,669,000 after buying an additional 607,972 shares during the period.
In other DexCom news, Director Mark G. Foletta sold 2,500 shares of the stock in a transaction on Monday, November 27th. The stock was sold at an average price of $54.95, for a total transaction of $137,375.00. Following the completion of the transaction, the director now directly owns 4,952 shares of the company’s stock, valued at approximately $272,112.40. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Andrew K. Balo sold 3,244 shares of the stock in a transaction on Monday, September 11th. The shares were sold at an average price of $72.27, for a total value of $234,443.88. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 37,954 shares of company stock valued at $2,266,296. 1.70% of the stock is currently owned by corporate insiders.
Several equities research analysts have recently weighed in on DXCM shares. Northland Securities downgraded DexCom from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $85.00 to $60.00 in a research report on Thursday, September 28th. Wedbush reaffirmed a “buy” rating and issued a $76.00 target price on shares of DexCom in a research report on Wednesday, October 4th. Zacks Investment Research downgraded DexCom from a “hold” rating to a “sell” rating in a research report on Tuesday, October 24th. Robert W. Baird reiterated a “hold” rating and issued a $79.00 price target on shares of DexCom in a research note on Sunday, September 10th. Finally, Morgan Stanley cut their price target on DexCom from $72.00 to $52.00 and set a “neutral” rating on the stock in a research note on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the company’s stock. DexCom presently has a consensus rating of “Buy” and an average price target of $70.69.
DexCom, Inc. (NASDAQ DXCM) opened at $61.53 on Friday. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50. DexCom, Inc. has a one year low of $42.62 and a one year high of $88.80.
WARNING: “First Trust Advisors LP Lowers Holdings in DexCom, Inc. (DXCM)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/10/first-trust-advisors-lp-lowers-holdings-in-dexcom-inc-dxcm.html.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.